Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-10-17 DOI:10.1111/apt.18251
Nikolaos Papadopoulos, Melanie Deutsch
{"title":"Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C","authors":"Nikolaos Papadopoulos,&nbsp;Melanie Deutsch","doi":"10.1111/apt.18251","DOIUrl":null,"url":null,"abstract":"<p>The global fight against viral hepatitis started in 2016 and, based on the WHO's strategy to reduce infection rate by 90% and deaths by 65% until 2030, has made significant strides recently. Despite this fact, the Global Hepatitis Report in 2024 reveals that viral hepatitis killed over a million people last year, so there is still a lot of job to do to overcome barriers worldwide.<span><sup>1, 2</sup></span> In this context, independent of every country's politics, microelimination efforts have proved quite effective and useful.</p><p>Under this aim, the authors of a recent paper in AP&amp;T used an intelligent method to identify hepatitis patients (not only C but also B and D) who were not linked to care.<span><sup>3</sup></span> They retrieved the records of 3731 patients from the Central Laboratory database of the Northern Barcelona Health Area and identified an alarming gap between diagnosis and management of hepatitis cases. Respectively, 38% HBsAg, 29% anti-δ positive and 59% HCV RNA positive individuals did not receive the appropriate care. The disconnection between diagnosis and healthcare delivery demonstrates how intricate it is to deal with chronic viral hepatitis, whereby the impediments differ according to patient populations affected.<span><sup>1</sup></span></p><p>Next, the authors proceeded a step further and tried to reintegrate the lost patients by systematically identifying and contacting them (up to 5 telephone calls and by post!). Finally, 47.2% of eligible patients (64% hepatitis B, 27% C and 100% D) were successfully linked to care. This is one of the most impressive aspects of the study that looks into whether a targeted intervention strategy is effective or not. The results can be considered a great success, especially regarding the ‘new (old) kid in town’—hepatitis D, which is mostly underdiagnosed but happens to be in the most severe among viral hepatitis infections.</p><p>So, can even the most challenging cases be brought back into care with the right approach? This is less true regarding hepatitis C patients, who present considerable difficulties in re-engaging. In fact, social factors such as instability, unwillingness to use healthcare services and outmoded beliefs about treatment challenges contributed to a lower success rate. All interventions targeting this population should therefore encompass more than clinical strategies to address the social determinants of health that impede patient engagement.<span><sup>4</sup></span> Better coordination of patient data across regions is one key recommendation to help keep track of patients who move and maintain continuity of care. Additionally, closer integration of social services with health care can provide the necessary assistance to bring back socially marginalized patients as well as those who have lost trust in the healthcare system.</p><p>As the global health community continues its efforts to eliminate viral hepatitis, there is a clear reminder of how far we have to go.<span><sup>5</sup></span> However, this type of research provides useful insights into overcoming obstacles by addressing barriers to linkage to care and developing interventions that are tailored for different target populations with any type of viral hepatitis.</p><p><b>Nikolaos Papadopoulos:</b> Writing – original draft; investigation; resources. <b>Melanie Deutsch:</b> Supervision; writing – review and editing; conceptualization.</p><p>None.</p><p>This article is linked to Vargas-Accarino et al paper. To view this article, visit https://doi.org/10.1111/apt.18227.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"60 10","pages":"1451-1452"},"PeriodicalIF":6.6000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18251","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18251","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The global fight against viral hepatitis started in 2016 and, based on the WHO's strategy to reduce infection rate by 90% and deaths by 65% until 2030, has made significant strides recently. Despite this fact, the Global Hepatitis Report in 2024 reveals that viral hepatitis killed over a million people last year, so there is still a lot of job to do to overcome barriers worldwide.1, 2 In this context, independent of every country's politics, microelimination efforts have proved quite effective and useful.

Under this aim, the authors of a recent paper in AP&T used an intelligent method to identify hepatitis patients (not only C but also B and D) who were not linked to care.3 They retrieved the records of 3731 patients from the Central Laboratory database of the Northern Barcelona Health Area and identified an alarming gap between diagnosis and management of hepatitis cases. Respectively, 38% HBsAg, 29% anti-δ positive and 59% HCV RNA positive individuals did not receive the appropriate care. The disconnection between diagnosis and healthcare delivery demonstrates how intricate it is to deal with chronic viral hepatitis, whereby the impediments differ according to patient populations affected.1

Next, the authors proceeded a step further and tried to reintegrate the lost patients by systematically identifying and contacting them (up to 5 telephone calls and by post!). Finally, 47.2% of eligible patients (64% hepatitis B, 27% C and 100% D) were successfully linked to care. This is one of the most impressive aspects of the study that looks into whether a targeted intervention strategy is effective or not. The results can be considered a great success, especially regarding the ‘new (old) kid in town’—hepatitis D, which is mostly underdiagnosed but happens to be in the most severe among viral hepatitis infections.

So, can even the most challenging cases be brought back into care with the right approach? This is less true regarding hepatitis C patients, who present considerable difficulties in re-engaging. In fact, social factors such as instability, unwillingness to use healthcare services and outmoded beliefs about treatment challenges contributed to a lower success rate. All interventions targeting this population should therefore encompass more than clinical strategies to address the social determinants of health that impede patient engagement.4 Better coordination of patient data across regions is one key recommendation to help keep track of patients who move and maintain continuity of care. Additionally, closer integration of social services with health care can provide the necessary assistance to bring back socially marginalized patients as well as those who have lost trust in the healthcare system.

As the global health community continues its efforts to eliminate viral hepatitis, there is a clear reminder of how far we have to go.5 However, this type of research provides useful insights into overcoming obstacles by addressing barriers to linkage to care and developing interventions that are tailored for different target populations with any type of viral hepatitis.

Nikolaos Papadopoulos: Writing – original draft; investigation; resources. Melanie Deutsch: Supervision; writing – review and editing; conceptualization.

None.

This article is linked to Vargas-Accarino et al paper. To view this article, visit https://doi.org/10.1111/apt.18227.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
社论:消除病毒性肝炎:仍然是一个巨大的挑战:护理不仅针对丙型肝炎
本文链接至 Vargas-Accarino 等人的论文。如需查看本文,请访问 https://doi.org/10.1111/apt.18227。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA Serum Ferritin Levels and Liver-Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1